Van ECK Associates Corp increased its holdings in CVS Health by 3.3% in the third quarter. Following the completion of the purchase, the director now owns 101,252 shares of the company's stock, valued at approximately $6,276,611.48.
Earnings per Share Details of CVS Health Corporation: The EPS of CVS is strolling at 5.05, measuring its EPS growth this year at 1.8%. The stock grabbed 113 new institutional investments totaling 10,227,703 shares while 149 institutional investors sold out their entire positions totaling 9,844,304 shares.
Want to see what other hedge funds are holding CVS? Wealthcare Advisory Partners LLC now owns 1,291 shares of the pharmacy operator's stock valued at $105,000 after buying an additional 991 shares in the last quarter. The Manufacturers Life Insurance Company now owns 4,818,244 shares of the pharmacy operator's stock valued at $349,322,000 after purchasing an additional 2,889,561 shares in the last quarter. Vigilant Capital Management Llc who had been investing in Cvs Health Corp for a number of months, seems to be less bullish one the $71.26B market cap company.
The company now has an insider ownership of 0.1 Percent and Institutional ownership of 86 Percent. The shares were purchased at an average cost of $61.99 per share, with a total value of $619,900.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website.
Profitability Ratios (ROE, ROA, ROI): Looking into the profitability ratios of CVS stock, an investor will find its ROE, ROA, ROI standing at 18.3%, 6.4% and 9.9%, respectively. 13,025,161 shares of the company traded hands, compared to its average volume of 7,083,725.
CVS Health Corporation (NYSE:CVS) has made a 16.54% comeback from a 12-month low price of $60.14. The company has a current ratio of 2.37, a quick ratio of 1.88 and a debt-to-equity ratio of 1.59.
Analysts await CVS Health Corporation (NYSE:CVS) to report earnings on August, 14. Analysts are forecasting earnings of $1.61 on a per share basis this quarter. CVS Health had a return on equity of 17.45% and a net margin of 3.59%. The business had revenue of $45.69 billion during the quarter, compared to the consensus estimate of $45.77 billion. It also reduced its holding in Berkshire Hath B (BRKB) by 2,134 shares in the quarter, leaving it with 184,047 shares, and cut its stake in Intel Corp (NASDAQ:INTC). To make a proper assessment, investors seek a sound estimate of this year's and next year's earnings per share (EPS), as well as a strong sense of how much the company will earn even farther down the road.
CVS Pharmacy said in a statement it's the first national retailer to offer prescription delivery. Bank of America dropped their price objective on CVS Health from $91.00 to $88.00 and set a "buy" rating on the stock in a research report on Wednesday, April 11th. Raymond James upgraded the shares of CVS in report on Thursday, January 4 to "Buy" rating. Finally, Loop Capital set a $68.00 price objective on shares of CVS Health and gave the company a "hold" rating in a research report on Monday, May 7th. Finally, Mizuho set a $95.00 target price on CVS Health and gave the company a "buy" rating in a research note on Wednesday, June 13th.
CVS Health Corporation (CVS) has been given an average price target of $86.8 from analysts, according to data collected by Finviz. The Company serves employers, insurance companies, unions, government employee groups, managed care organizations and other sponsors of health benefit plans, and individuals under the CVS Caremark Pharmacy Services, Caremark, CVS Caremark, CarePlus CVS/pharmacy, RxAmerica, Accordant, SilverScript, and Novologix names.